gasguide

/practice/journal-club / 2018

NAP6: UK Perioperative Anaphylaxis Registry

Cook TM et al. Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features (NAP6). Br J Anaesth 2018;121:159-171.

anaphylaxis · registry · drug-allergy

Hook

Antibiotics + NMBs cause most perioperative anaphylaxis; rocuronium leads in many series.

Population, Intervention, Comparison, Outcome

Population
266 cases of Grade 3-5 perioperative anaphylaxis collected over 1 year across the UK NHS.
Intervention
Observational — drug exposures, presenting features, treatments documented.
Comparison
n/a — descriptive epidemiology.
Outcome
Trigger drug attribution, presenting signs, time-to-treatment, mortality.

Methods

Prospective national registry across 342 UK hospitals over 12 months. Cases referred for tryptase + skin testing for drug attribution. Multidisciplinary review for inclusion.

Findings

  • Antibiotics: 47% of cases (teicoplanin + co-amoxiclav prominent).
  • NMBs: 33% (succinylcholine + atracurium more than rocuronium in UK practice — different profile from French GERAP data).
  • Chlorhexidine: 9%.
  • Patent blue dye: 5%.
  • Mortality: 3.5% — concentrated in delayed recognition + delayed epinephrine.
  • Hypotension was the presenting sign in ~47%; bronchospasm in ~18%; rash in only ~50% (often missed under drapes).

Clinical takeaway

Suspect anaphylaxis in unexplained intraoperative hypotension regardless of rash. Give epinephrine FIRST (50-100 mcg IV bolus, repeat or infuse 0.05-0.1 mcg/kg/min); fluid 1-2 L; H1 + H2 + steroid as adjuncts. Tryptase at 1-2 hr + 24 hr confirms diagnosis. Refer all suspected cases to allergist for drug skin testing — never label a drug 'allergy' on a chart without confirmation, but never re-expose without skin testing if the index event was Grade 3+.

Limitations

  • UK-specific drug exposure patterns (teicoplanin > vancomycin; rocuronium less prominent than in France).
  • Reliance on referral may underestimate incidence.
  • Skin testing has imperfect sensitivity; some attributions are presumptive.

Discussion questions

  1. Does your facility have a perioperative anaphylaxis pathway including tryptase timing + allergist follow-up?
  2. How do you handle the patient with 'PCN allergy' on chart — do you skin-test before re-exposure or default to vancomycin?
  3. Are you confident your drape-up workflow doesn't hide an evolving rash for 30+ minutes?

← Back to all articles